Clinical Trials

Multiple clinical trials evaluate ropivacaine for localized pain management and regional blockade across conditions such as postoperative pain, colorectal cancer, and bunions. Ranging from Phase 3 and Phase 4 evaluations to unclassified protocols, these studies include active statuses such as recruiting and not yet recruiting. Key academic and industrial sponsors behind these investigations include The University of Hong Kong, West China Hospital, PainReform LTD, and Lotus Clinical Research LLC.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04003506 Not yet recruiting
Pain Postoperative
The University of Hong Kong
 2024-03-01 Phase 4
NCT06006026 Recruiting
Colorectal Cancer
West China Hospital
 2023-08-28 Not Applicable
NCT05773846 Recruiting
Bunion
PainReform LTD|Lotus Clinical Research LLC
 2023-03-13 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Ropivacaine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ropivacaine reversibly binds to voltage-gated sodium channels in nerve axons, blocking intracellular sodium influx and preventing action potential propagation. This interruption of neuronal signal conduction produces effective localized sensory anesthesia, suppressing surgical and postoperative pain in conditions such as bunion surgery and colorectal procedures.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.